Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2025 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308...
November 13, 2025 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate...
October 14, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...
August 14, 2025 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics Reports Q2 2025 Results and Business Update